|
[1]
|
Chen QL, Rodewald L, Lai SJ, Gao GF. Rapid and sustained containment of COVID-19 is achievable and worthwhile: implications for pandemic response. BMJ 2021;375:e066169. http://dx.doi.org/10.1136/BMJ-2021-066169CrossRef
|
|
[2]
|
An ZJ, Wang FJ, Pan A, Yin ZD, Rodewald L, Feng ZJ. Vaccination strategy and challenges for consolidating successful containment of COVID-19 with population immunity in China. BMJ 2021;375:e066125. http://dx.doi.org/10.1136/bmj-2021-066125CrossRef
|
|
[3]
|
Zhou Y, Yang Q, Chi JW, Dong BZ, Lv WS, Shen LY, et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: a systematic review and meta-analysis. Int J Infect Dis 2020;99:47 − 56. http://dx.doi.org/10.1016/j.ijid.2020.07.029CrossRef
|
|
[4]
|
Morens DM, Folkers GK, Fauci AS. The concept of classical herd immunity May not apply to COVID-19. J Infect Dis 2022;226(2):195 − 8. http://dx.doi.org/10.1093/infdis/jiac109CrossRef
|
|
[5]
|
Wan EYF, Wang Y, Chui CSL, Mok AHY, Xu WC, Yan VKC, et al. Safety of an inactivated, whole-virion COVID-19 vaccine (CoronaVac) in people aged 60 years or older in Hong Kong: a modified self-controlled case series. Lancet Healthy Longev 2022;3(7):e491 − 500. http://dx.doi.org/10.1016/S2666-7568(22)00125-8CrossRef
|
|
[6]
|
Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med 2021;385(10):875 − 84. http://dx.doi.org/10.1056/NEJMoa2107715CrossRef
|
|
[7]
|
Al Kaabi N, Oulhaj A, Ganesan S, Al Hosani FI, Najim O, Ibrahim H, et al. Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates. Nat Commun 2022;13(1):3215. http://dx.doi.org/10.1038/s41467-022-30835-1CrossRef
|
|
[8]
|
Ma C, Sun WW, Tang TT, Jia MH, Liu YH, Wan YF, et al. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: evidence from an outbreak in Yunnan, China, 2021. Vaccine 2022;40(20):2869-74. http://dx.doi.org/10.1016/j.vaccine.2022.03.067.http://dx.doi.org/10.1016/j.vaccine.2022.03.067 |
|
[9]
|
Kang M, Yi Y, Li Y, Sun LM, Deng AP, Hu T, et al. Effectiveness of inactivated COVID-19 vaccines against illness caused by the B. 1.617.2 (Delta) variant during an outbreak in Guangdong, China: a cohort study. Ann Intern Med 2022;175(4):533 − 40. http://dx.doi.org/10.7326/M21-3509CrossRef
|
|
[10]
|
Wu D, Zhang YY, Tang L, Wang FZ, Ye Y, Ma C, et al. Effectiveness of inactivated COVID-19 vaccines against symptomatic, pneumonia, and severe disease caused by the delta variant: real world study and evidence — China, 2021. China CDC Wkly 2022;4(4):57 − 65. http://dx.doi.org/10.46234/ccdcw2022.009CrossRef
|
|
[11]
|
Fan XB, Lu S, Bai L, Liu HC, Fu JS, Jin XX, et al. Preliminary study of the protectiveness of vaccination against the COVID-19 in the outbreak of VOC omicron BA.2 — Jilin City, Jilin Province, China, March 3–April 12, 2022. China CDC Wkly 2022;4(18):377 − 80. http://dx.doi.org/10.46234/ccdcw2022.081CrossRef
|
|
[12]
|
Wu D, Ye Y, Tang L, Wang AB, Zhang R, Qian ZH, et al. A case-case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by delta and omicron variants. Emerg Microbes Infect 2022;11(1):1950 − 8. http://dx.doi.org/10.1080/22221751.2022.2103455CrossRef
|
|
[13]
|
McMenamin ME, Nealon J, Lin Y, Wong JY, Cheung JK, Lau EHY, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect Dis 2022. http://dx.doi.org/10.1016/S1473-3099(22)00345-0.http://dx.doi.org/10.1016/S1473-3099(22)00345-0 |
|
[14]
|
Cheng FWT, Fan M, Wong CKH, Chui CSL, Lai FTT, Li X, et al. The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases. Kidney Int 2022. http://dx.doi.org/10.1016/j.kint.2022.07.018.http://dx.doi.org/10.1016/j.kint.2022.07.018 |
|
[15]
|
Wan EYF, Mok AHY, Yan VKC, Wang B, Zhang R, Hong SN, et al. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: A case control study. J Infect 2022. http://dx.doi.org/10.1016/j.jinf.2022.08.008CrossRef
|
|
[16]
|
Huang ZY, Xu SF, Liu JC, Wu LL, Qiu J, Wang N, et al. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death. medRxiv 2022. http://dx.doi.org/10.1101/2022.09.04.22279587CrossRef
|
|
[17]
|
Li MS, Liu QQ, Wu D, Tang L, Wang XQ et al. Association of COVID-19 vaccination and clinical severity of patients infected with Delta or Omicron variants – China May 21, 2021 – February 28, 2022. China CDC Weekly 2022;4(4):293 − 297. http://dx.doi.org/10.46234/ccdcw2022.074CrossRef
|
|
[18]
|
Orenstein W. Vaccines don’t save lives. Vaccinations save lives. Hum Vaccin Immunother 2019;15(12):2786 − 9. http://dx.doi.org/10.1080/21645515.2019.1682360CrossRef
|
|
[19]
|
Zavala E, Krubiner CB, Jaffe EF, Nicklin A, Gur-Arie R, Wonodi C, et al. Global disparities in public health guidance for the use of COVID-19 vaccines in pregnancy. BMJ Glob Health 2022;7(2):e007730. http://dx.doi.org/10.1136/bmjgh-2021-007730CrossRef
|
|
[20]
|
Paixao ES, Wong KLM, Alves FJO, De Araújo Oliveira V, Cerqueira-Silva T, Júnior JB, et al. CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study. BMC Med 2022;20(1):146. http://dx.doi.org/10.1186/s12916-022-02353-wCrossRef
|